Log in or Sign up for Free to view tailored content for your specialty!
Cancer Prevention News
Humana to cover Cologuard for colorectal cancer screening
Starting January 1, 2017, Humana will cover Cologuard, the FDA-approved multi-target stool DNA test for noninvasive colorectal cancer screening, as an in-network service for its members, most of whom will have access to the test with no co-pay, the manufacturer announced.
Expanding use of aspirin may benefit older adults at CVD risk
For older Americans with high risk for CVD, daily use of low-dose aspirin could result in reduced MI risk, prevention of cancer onset and cancer death, and savings of $692 billion in health care costs over 20 years, according to an analysis.
Log in or Sign up for Free to view tailored content for your specialty!
Aspirin does not appear to increase risk for fatal GI bleeding
While gastrointestinal bleeding is the most common adverse event caused by preventive low-dose aspirin regimens, there is no evidence that aspirin increases the frequency of fatal gastrointestinal bleeding, according to a systematic review and meta-analysis.
Moffitt Cancer Center study on e-cigarette use may help ‘take a bite’ out of smoking deaths
Moffitt Cancer Center has initiated a nationwide study of individuals who use both conventional and electronic cigarettes.
Sessile serrated polyps share risk factors with conventional adenomas
Some of the same modifiable lifestyle factors associated with the risk for developing conventional adenomas are also associated with the risk for sessile serrated polyps, according to a study led by researchers from Vanderbilt University School of Medicine.
Financial incentives fail to improve colorectal cancer screening
Offering $5 or $10 as an incentive for responding to a mailed invitation to undergo a fecal immunochemical test had no effect on colorectal cancer screening rates, according to a study published in “The Negative Issue” of the American Journal of Gastroenterology, a special edition focusing on what physicians should not do in clinical practice.
Two-dose regimens of Gardasil 9 noninferior to three-dose regimens
Two-dose regimens of Gardasil 9 separated by 6 or 12 months in girls and boys aged 9 to 14 years were noninferior compared with a three-dose regimen of the 9-valent HPV vaccine delivered over 6 months in adolescent girls and young women aged 16 to 26 years, according to the results of a clinical trial.
Cytosponge, biomarker panel predicts Barrett's progression
Using a non-endoscopic device touted as a “sponge-on-a-string” test, researchers were able to identify patients with Barrett’s esophagus who have a low risk for progression to esophageal cancer, allowing them to avoid endoscopic evaluation.
American Cancer Society honors three from Fox Chase
The American Cancer Society honored three people affiliated with Fox Chase Cancer Center.
Great American Smokeout: The latest on tobacco cessation research
Nov. 17 is the American Cancer Society’s Great American Smokeout. The annual event, held on the third Thursday of each November, is geared towards getting smokers to plan to quit.
-
Headline News
First US case of clade I mpox reported in California
November 18, 20242 min read -
Headline News
'On the frontlines of public health': Physicians leverage trust against firearm violence
November 19, 20246 min read -
Headline News
Data support early, continued lecanemab dosing for Alzheimer’s
November 19, 20242 min read
-
Headline News
First US case of clade I mpox reported in California
November 18, 20242 min read -
Headline News
'On the frontlines of public health': Physicians leverage trust against firearm violence
November 19, 20246 min read -
Headline News
Data support early, continued lecanemab dosing for Alzheimer’s
November 19, 20242 min read